Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atigotatug
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Atigotatug (BMS-986012) is a first-in-class, fully human IgG1 monoclonal antibody developed by Bristol Myers Squibb for the treatment of small cell lung cancer (SCLC). It specifically binds to fucosyl-GM1, a ganglioside that is highly expressed on SCLC tumor cells but has limited expression in normal tissues. The drug works primarily through antibody-dependent cell-mediated cytotoxicity (ADCC) mechanisms. It is being investigated both as a monotherapy and in combination with nivolumab (Opdivo). The drug is administered intravenously and has shown a manageable safety profile in clinical trials conducted to date.
- Other names
- AtigotatugAnti-fucosyl-GM1 antibodyAnti-fucosyl-GM-1 antibodyAnti-fucosyl-GM 1 antibodyFucosyl-GM1 antibodyFucosyl-GM-1 antibodyFucosyl-GM 1 antibody
02
Targets
Fuc-GM1 (Fucosyl-GM1 ganglioside)
Beyond the preview
Go deeper on Atigotatug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atigotatug.